9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search

A Study of ABBV-181 in Participants With Advanced Solid Tumors

Estimated reading time: < 1 min

Condition

Advanced Solid Tumors

Estimated Enrollment: 158

Age Group: 18 Years to 99 Years   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment

Study ID Numbers: M15-891|2016-002520-89

Study First Received: December 15, 2016

Last Updated: March 21, 2017

Estimated Primary Completion Date: June 2018

Primary Outcome Measures:

Number of participants with adverse events|Recommended Phase 2 Dose (RPTD) for ABBV-181|Maximum tolerated dose (MTD) of ABBV-181|Maximum observed serum concentration (Cmax)|Time to Cmax (Tmax)|Area under the serum concentration time curve (AUC)|Terminal half-life (t1/2)|Objective response rate (ORR)|Clinical benefit rate (CBR, defined as CR, PR or SD)|Progression-free survival (PFS)|Duration of objective response (DOR)

Sponsors and Collaborators:

AbbVie

Result Received: No Study Results Posted

Website Link: https://ClinicalTrials.gov/show/NCT03000257

Was this article helpful?
Views: 26